Evaluation of ventricular function by echocardiography and radionuclide angiography in patients treated with mitoxantrone

F. Villani, M. Galimberti, F. Crippa

Research output: Contribution to journalArticle

Abstract

Mitoxantrone, an anthracenedione derivative structurally similar to anthracycline, was tested in 25 Phase II patients with advanced breast cancer, previously treated with different cycles of 5-fluorouracil. Cardiac toxicity was evaluated by means of electrocardiography, echocardiography and radionuclide left-ventricular ejection fraction. Ten patients received a cumulative dose less than 70 mg/m2 (median 33.6, range 28-63) and 15 a dose equal to or more than 70 mg/m2 (median 81, range 70-84). ECG abnormalities in the form of dysrhythmias and ST-T changes were observed in 41% of the patients.Echocardiographic myocardial function parameters recorded in 10 of the 15 patients who received more than 70 mg/m2 demonstrated a trend to deterioration, whereas the nuclear angiographic ejection fraction recorded in all 15 patients who had more than 70 mg/m2 had significantly decreased. No patients developed congestive heart failure but almost one-quarter of them had a fall in myocardial function parameters of more than 15% compared to pretreatment values. These data indicate that mitoxantrone has a significant toxic effect on myocardial cells also at cumulative doses of less than 85 mg/m2 which is generally considered beyond the limit of safety for patients without risk factors.

Original languageEnglish
Pages (from-to)501-506
Number of pages6
JournalDrugs under Experimental and Clinical Research
Volume15
Issue number10
Publication statusPublished - 1989

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology (medical)
  • Drug Discovery
  • Pharmacology

Fingerprint Dive into the research topics of 'Evaluation of ventricular function by echocardiography and radionuclide angiography in patients treated with mitoxantrone'. Together they form a unique fingerprint.

  • Cite this